Cost-minimisation analysis of sivelestat for acute lung injury associated with systemic inflammatory response syndrome

PharmacoEconomics

Volumn 23, Issue 2, 2005, Pages 169-181

  Aikawa, Naoki ^a   Fujishima, Seitaro ^a   Kobayashi, Makoto ^b   Matsuoka, Shozo ^c,d   Abiru, Taira ^c  

^a KEIO UNIVERSITY   (Japan)

^b Crecon Research and Consulting Inc   (Japan)

^c ONO PHARMACEUTICAL CO   (Japan)

^d NONE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; AMINOTORIPA; ANTITHROMBIN III; BROMHEXINE; CARDIOTONIC AGENT; CILASTATIN PLUS IMIPENEM; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; ELECTROLYTE; EXPECTORANT AGENT; FAMOTIDINE; FLUCONAZOLE; FRESH FROZEN PLASMA; FUROSEMIDE; GABEXATE MESILATE; GLUCOSE; HEPARIN; HUMAN ALBUMIN; IMMUNOGLOBULIN; INSULIN; KENKETSU VENOGLOBULIN; METHYLPREDNISOLONE SODIUM SUCCINATE; MIDAZOLAM MALEATE; MULTAMIN; MUSCULAX; PLASMA PROTEIN; PLASMA PROTEIN FRACTION; PROPOFOL; RETINOL; SEDATIVE AGENT; SIVELESTAT; VECURONIUM;

ACUTE LUNG INJURY; ADOLESCENT; ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST MINIMIZATION ANALYSIS; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG COST; FEMALE; HUMAN; INFECTION; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NATIONAL HEALTH INSURANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COST SAVINGS; FEMALE; GLYCINE; HEALTH CARE COSTS; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; RESPIRATORY DISTRESS SYNDROME, ADULT; SULFONAMIDES; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 16244413935     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200523020-00008     Document Type: Article

References (9)

1. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992 Jun; 101 (6): 1644-55
2. Sun D, Aikawa N. The natural history of the systemic inflammatory response syndrome and the evaluation of SIRS criteria as a predictor of severity in patients hospitalised through emergency services. Keio J Med 1999; 48 (1): 28-37
3. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994 Mar; 149 (3 Pt 1); 818-24
4. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000 May; 342 (18): 1334-49
5. Kawabata K, Hagio T, Matsuoka S. The role of neutrophil elastase in acute lung injury. Eur J Pharmacol 2002; 451: 1-10
6. Tamakuma S, Shiba T, Hirasawa H, et al. A phase III clinical study of a neutrophil elastase inhibitor; ONO-5046•Na in SIRS patients [in Japanese]. Rinshoiyaku 1998 Feb; 14 (2): 289-318
7. Fujishima S, Aikawa N, Kobayashi M, et al. Cost analysis of ONO-5046•Na for acute lung injury associated with systemic inflammatory response syndrome [in Japanese]. Rinsho to Kenkyu 2002 Jul; 79 (7): 1251-8
8. Ishizawa Y, Dohi S, Mizutani T, et al. An investigation of patients with hematological disorders who need the ICU management [in Japanese]. Nihon Iji Shinpo 1990; 3479: 47-50
9. Sofianou DC, Constandinidis TC, Yannacou M, et al. Analysis of risk factors for ventilator-associated pneumonia in a multidisciplinary intensive care unit. Eur J Clin Microbiol Infect Dis 2000 Jun; 19 (6): 460-3